Stock Events

Stock Events

Bio Green Med Solution 

$0.95
0
-$0.01-0.96% Today

Statistics

Day High
0.95
Day Low
0.95
52W High
-
52W Low
-
Volume
160
Avg. Volume
-
Mkt Cap
4.67M
P/E Ratio
-
Dividend Yield
15.58%
Dividend
0.15

Upcoming

29
APR
Dividend Ex
Estimated
 
1
MAY
Dividend Payment
Estimated
 
29
APR 27
Dividend Ex
Estimated
 
30
APR 27
Dividend Payment
Estimated
 
1
MAY 28
Dividend Ex
Estimated
 

Dividends

15.58%Dividend Yield
May 26
$0.15
May 25
$0.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13MayExpected
Q3 2025
Next
-72
-48.44
-24.87
-1.31
Expected EPS
N/A
Actual EPS
N/A

Financials

-26,074.42%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
86,000Revenue
-22.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGMS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as oncology, where Cyclacel also operates.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on human therapeutics, including treatments for cancer, which puts it in direct competition with Cyclacel's oncology focus.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer treatments that compete with Cyclacel's product pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad portfolio, including oncology, directly competing with Cyclacel's cancer-focused therapies.
Merck
MRK
Mkt Cap214.76B
Merck is known for its high-quality research and development in pharmaceuticals, including cancer drugs, making it a competitor to Cyclacel.
Novartis
NVS
Mkt Cap237.61B
Novartis is a healthcare company that focuses on innovative medicines, with a strong emphasis on oncology, competing with Cyclacel in the cancer treatment market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the discovery of new medicines, including for cancer, directly competing with Cyclacel's research and development in oncology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including in oncology, competing with Cyclacel.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a pioneer in healthcare, with a strong focus on pharmaceuticals and diagnostics in oncology, making it a competitor to Cyclacel.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diverse healthcare company that has a pharmaceutical segment involved in the development of oncology treatments, competing with Cyclacel.

About

A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Show more...
CEO
ISIN
US23254L8761

Listings

XNAS
US
BGMS
OTC Link
US
BGMSP
BOATS
BOATS
BGMS.BOATS

0 Comments

Share your thoughts

FAQ

What is Bio Green Med Solution stock price today?▼
The current price of BGMS.BOATS is $0.95 USD — it has decreased by -0.96% in the past 24 hours. Watch Bio Green Med Solution stock price performance more closely on the chart.
What is Bio Green Med Solution stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bio Green Med Solution stocks are traded under the ticker BGMS.BOATS.
What is Bio Green Med Solution market cap?▼
Today Bio Green Med Solution has the market capitalization of 4.67M
When is the next Bio Green Med Solution earnings date?▼
Bio Green Med Solution is going to release the next earnings report on May 13, 2026.
What were Bio Green Med Solution earnings last quarter?▼
BGMS.BOATS earnings for the last quarter are -1.31 USD per share, whereas the estimation was -72 USD resulting in a +98.18% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bio Green Med Solution revenue for the last year?▼
Bio Green Med Solution revenue for the last year amounts to 86,000 USD.
What is Bio Green Med Solution net income for the last year?▼
BGMS.BOATS net income for the last year is -22.42M USD.
Does Bio Green Med Solution pay dividends?▼
Yes, BGMS.BOATS dividends are paid annual. The last dividend per share was 0.15 USD. As of today, Dividend Yield (FWD)% is 15.58%.
When did Bio Green Med Solution complete a stock split?▼
Bio Green Med Solution has not had any recent stock splits.